Skip to main content
Rahko logo

Rahko

Company · London

Rahko was a London quantum machine learning start-up founded in 2018 by UCL computer science graduates. Its Hyrax drug discovery service paired machine learning and quantum algorithms with computational chemistry, and it worked with AWS, IBM, Nvidia and Microsoft. In December 2021 Odyssey Therapeutics, a Boston biotech that had just raised $218m, took a majority stake in the company, which then had about a dozen staff.

Rahko, based in London, is a company whose work covers quantum software; it was founded in 2018. It is now part of Odyssey Therapeutics. It is not yet linked to a UK project in this directory.

Sources: Quantum computing funds Rahko drug discovery buyout | Quantum Zeitgeist

Compare with others

Profile last checked 2 October 2026

Projects (0)

No project in this directory lists Rahko as lead, partner or funder yet.

In the news

Recent articles from Quantum Zeitgeist that mention Rahko.

  • The British Quantum Invasion

    The British Quantum Invasion, read on Quantum Zeitgeist

    The UK is emerging as a global leader in the field of quantum computing, with several companies leading the charge in this technological revolution, known as the ‘British Quantum Invasion’. Companies like PsiQuantum are leveraging existing semiconductor manufacturing techniques to build fault-tolera

    Image © Quantum Zeitgeist

  • · UK

    Quantum Computing Funds Rahko Drug Discovery Buyout, read on Quantum Zeitgeist

    In yet another breakthrough for the world of Quantum Technology. As Quantum Computers are starting to be utilized. Billions of fundings are being raised for its further developments. Rahko, a London-based company with only a dozen members, established in 2018, has made a cutting-edge innovation of u

    Image © Quantum Zeitgeist

Similar organisations

Chosen by shared specialisms, then location and type.

Company data from Entangled Future. News from Quantum Zeitgeist. Last checked 2 October 2026.

Logos and names are trademarks of their respective owners, used to identify them. No endorsement implied.